Both the IDH1 wild type (12.2 months TMZ not used vs 32.7 months TMZ used) and mutant IDH1 (18.8 months TMZ not used vs 57.1 months TMZ used) showed significant difference with respect to use of TMZ chemotherapy and in fact showed better OS when chemotherapy was used across all histological types of glioma patients (log-rank p < 0.05). The gene discussed is IDH1; the disease is glioma.